1756 results about "Adenosine" patented technology

The invention relates to an enzymology measuring method and reagent with circular increment technology, applied to measure the content of homeotypic cysteine in the measured sample. The character is: with a circular increment technology, increases the measurement sensitivity, thus it can carries on automatic measurement to the homeotypic cysteine in the sample liquid like normal enzymology diagnosing agent. The homeotypic cysteine in the sample liquid reacts with the S-adenosine-L-methionine repeatedly and circularly under the effect of homeotypic cysteine methyl kinase and adenosine homeotypic cysteine, generates the adenosine, the speed of the adenosine generation is in direct proportion to the homeotypic cysteine in the sample, through the generation speed, the aim to measure the content of the homeotypic cysteine in sample can be achieved.

The present invention relates to a series of substituted indole derivatives of the formula I:

• • wherein R, R₁, R₂, R₃, R₄, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.

The present invention is directed to the use of a PDE4 inhibitor and a glucocorticoid to treat peripheral B-cell neoplasms. In particular, the present invention provides a method of treating individuals (e.g. patients) diagnosed with peripheral B-cell leukemias by administering pharmaceutical compositions comprising Type 4 cyclic adenosine monophosphate phosphodiesterase inhibitors and a glucocorticoid. Preferably, the combination of the PDE4 inhibitor and the glucocorticoid has a synergistic effect on apoptosis such that the level of apoptosis induced is greater than the level that would be expected by simply adding a PDE4 inhibitor to a glucocorticoid.

Personal care composition comprising from about 0.05% to about 5% of at least one aquaporin-stimulating compound selected from the group consisting of xanthine, caffeine; 2-amino-6-methyl-mercaptopurine; 1-methyl xanthine; 2-aminopurine; theophylline; theobromine; adenine; adenosine; kinetin; p-chlorophenoxyacetic acid; 2,4-dichlorophenoxyacetic acid; indole-3-butyric acid; indole-3-acetic acid methyl ester; beta-naphthoxyacetic acid; 2,3,5-triiodobenzoic acid; adenine hemisulfate; n-benzyl-9-(2-tetrahydropyranyl)adenine; 1,3-diphenylurea; 1-phenyl-3-(1,2,3-thiadiazol-5-yl)urea; zeatin; indole-3-acetic acid; 6-benzylaminopurine; alpha-napthaleneacetic acid; 6-2-furoylaminopurine; green tea extract; white tea extract; menthol; tea tree oil; ginsenoside-RB1; ginsenoside-RB3; ginsenoside-RC; ginsenoside-RD; ginsenoside-RE; ginsenoside-RG1; ginseng root extract; ginseng flower extract; pomegranate extract, extracts from Ajuga turkestanica; extracts from viola tricolor and combinations thereof; an additional ingredient selected from the group consisting of niacinamide, glycerin and mixtures thereof, and a dermatologically-acceptable carrier.

The invention provides compounds having the following general formula (I):

wherein X, R¹, R², R⁷ and Z are as described here.

A prophylactic and/or therapeutic agent for diseases accompanied by chronic musculoskeletal pain comprising as an active ingredient a compound having an adenosine A_2A receptor antagonistic action, for example, represented by the following formula (I) (wherein R¹, R² and R³ are the same or different, each representing a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl; R⁴ represents cycloalkyl, —(CH₂)_n—R⁵ or the following formula (II); and X¹ and X² are the same or different, each representing an oxygen atom or a sulfur atom) or a pharmaceutically acceptable salt thereof.

The invention provides compounds having the following general formula (I):

• • wherein X, R¹, R², R⁷ and Z are as described herein.

The present invention relates to pharmaceutical compositions comprising at least one multifunctional phosphodiesterase inhibitor (MPDEI) and at least one adenosine uptake inhibitor. The present invention also relates to compositions comprising cilostazol and dipyridamole and their use.

2-adenosine C-pyrazole compositions having the following formula:

and methods for using the compositions as A_2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.

Compositions of S-adenosyl-L-methionine with additives are disclosed.

A compound of the formula (I): wherein ring A is a carbocyclic group, R1 is hydrogen or a halogen atom or a lower alkyl group, R2 is a di(lower)alkylamino group or N-containing heterocyclic group, among which the N-containing heterocyclic group may be substituted with one or more substituent(s), Y is an oxygen or sulfur atom, n is an integer from 0 to 2, and m is an integer from 0 to 4, or its prodrug, or their salt which has poly(adenosine 5′-diphospho-ribose)polymerase inhibiting activity.

The invention relates to a novel method for breeding cordyceps militaris by utilizing silkworm larvae. The method comprises the steps of taking live matured silkworm as the host, vaccinating cordyceps militaris strains through an injection method, and promoting silkworm to sleep, and the vaccination attainment rate is improved; after the method is adopted, the inactivation rate of the silkworm larvae reaches 90% to 100%, and the outgrowth rate of fruiting body reaches 85% to 100%; moreover, the water-solubility protein, polysaccharide, cordycepic acid, cordycepin and adenosine of the cordyceps militaris bred by the method are higher than those of cordyceps militaris bred by silkworm chrysalis in content. The novel method for breeding cordyceps militaris by utilizing silkworm larvae has the advantages of convenience in operation, low breeding cost, good experiment repeatability and wide application prospect, and is suitable for large-scale cultivation.

This invention describes the large-scale fermentation and processing of Chinese caterpillar fungus. In this invention, hirsutella sinensis strains are used as the fermentation strain and cultivated in the inclined plate and shaking-bottle. 3-5% of potato, 0.5-2% of soybean powders, 0.01-0.02% of soifnum muicfun, 0.01-0.02% of Chinese yam, 0.5-2% of protein, 0.5-5% of glucose, a small amount of dipotassium hydrogen phosphorus and magnesium sulfate, and water culture medium are successively directed into all levels of fermenter for fermentation and processing. The yield of the fermented product is 20% higher than that in the present processes, the fermentation periodic time is 12 days shorter, the cost is 20% lower and the pollution rate is 2% lower. Through the DNA molecular sequence examination by the institute of microbes, Chinese Academy of Sciences, the constitution of the fermented product is the same with that of natural Chinese caterpillar fungus, and the content of cordycepin, adenosine, Chinese caterpillar fungus polyoses, sterol, biological base, amino acids and trace elements is much higher than that in natural Chinese caterpillar fungus. The pharmacological action of the fermented product is better than that of natural Chinese caterpillar fungus.

Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

Methods and compositions including combined use of a serine protease inhibitor and adenosine when administered as a single pharmaceutical composition, concomitantly or sequentially in any order to a living subject for preventing organ ischemia or reperfusion injury. The methods and compositions disclosed herein can be used in such procedures as cardiac surgery, non-surgical cardiac revascularization, organ transplantation, perfusion, ischemia, reperfusion, ischemia-reperfusion injury, oxidant injury, cytokine induced injury, shock induced injury, resuscitations injury or apoptosis.